
- Danish stocks
- Norwegian stocks
- Swedish stocks
- AktieTorget
- A1M Pharma
- Accelerator Nordic
- AlphaHelix
- AroCell
- Biotech-IgG
- Brighter
- Clinical Laserthermia
- Emotra
- Enzymtica
- Eurocine Vaccines
- European Inst. of Science
- IDL Biotech
- Medfield Diagnostics
- MedicPen
- MediRox
- MediRätt
- Micropos Medical
- PharmaLundensis
- Respiratorius
- Rubicon Life Science
- SensoDetect
- WntResearch
- Orasolv
- Senzime
- SPAGO Imaging
- Vivoline Medical
- First North Stockholm
- OMX Stockholm A-F
- OMX Stockholm G-Z
- AktieTorget
- US stocks
- General discussion
- All posts
However, plasma NGAL was the strongest predictor of AKI progression, with patients in the highest quintile (>322 ng/mL) being 7.7 times more likely to progress than those in the lowest two quintiles (60-164.5 ng/mL).
The article.
no small wonder that the proposed cut-off at 130 ng/ml proved futile. You will have a large number of false positive up until approx. 150
So Alere is risking their credibility in order to defend af undefendable cutoff-value…
It would have been som much easier (and cheaper in the long run) if they had stopped flogging the dead horse (CCH' revorked patent)